Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
CRSP Analyst Ratings
Moderate Buy
11 Buy
6 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CRSP Stock 12 Month Forecast
Average Price Target
$71.50
▲(8.79% Upside)
| Highest Price Target$99.00 | Average Price Target$71.50 | Lowest Price Target$40.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$80
Buy
21.73%
Upside
Reiterated
10/22/25
Bank of America Securities
$78→$93
Buy
41.51%
Upside
Reiterated
10/17/25
Truist Financial
―
Buy
―
Reiterated
10/13/25
Wells Fargo
$65→$75
Hold
14.12%
Upside
Reiterated
10/13/25
Citizens JMP
$86
Buy
30.86%
Upside
Reiterated
10/13/25
William Blair
―
Buy
―
Reiterated
10/10/25
Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical DataWe view the preclinical data on CTX460 positively as it suggests the therapy could enable patients to achieve AAT-M levels in the normal range, a feat that has not been achieved by other clinical assets to date. With CTX460 expected to enter the clinic in mid-2026, we see CRISPR as positioned to enter the clinic around the same time as Prime Medicine’s AATD program. However, while we believe that CRISPR’s approach and SYNTase technology are differentiated, we recognize the AATD development landscape is becoming increasingly crowded. Outside CTX460, we view CRISPR as having a catalyst-rich 12-month period ahead as Casgevy uptake continues and the company shares additional clinical data from its in vivo and ex vivo assets, including updated clinical data from CTX310 at AHA in November.
Needham
$81
Buy
23.25%
Upside
Reiterated
10/10/25
Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy RatingWe view the smaller size of the nucleic acid construct as an advantage leading potentially to higher editing efficiencies. Crispr intends to initiate clinical development mid-26' placing the company ~18 months behind Beam. Despite this advantage in timelines, demonstrating meaningfully higher serum AAT levels would support a competitive position. Disclaimers GIL BLUM, PH.D.
BMO Capital
$75
Buy
14.12%
Upside
Reiterated
09/23/25
J.P. Morgan
$70
Buy
6.51%
Upside
Initiated
09/18/25
Evercore ISI
$99
Buy
50.64%
Upside
Reiterated
08/25/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Chardan Capital
$82
Buy
24.77%
Upside
Reiterated
08/05/25
TD Cowen
$35→$40
Hold
-39.14%
Downside
Reiterated
08/05/25
Goldman Sachs
$48
Hold
-26.96%
Downside
Reiterated
08/05/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$80
Buy
21.73%
Upside
Reiterated
10/22/25
Bank of America Securities
$78→$93
Buy
41.51%
Upside
Reiterated
10/17/25
Truist Financial
―
Buy
―
Reiterated
10/13/25
Wells Fargo
$65→$75
Hold
14.12%
Upside
Reiterated
10/13/25
Citizens JMP
$86
Buy
30.86%
Upside
Reiterated
10/13/25
William Blair
―
Buy
―
Reiterated
10/10/25
Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical DataWe view the preclinical data on CTX460 positively as it suggests the therapy could enable patients to achieve AAT-M levels in the normal range, a feat that has not been achieved by other clinical assets to date. With CTX460 expected to enter the clinic in mid-2026, we see CRISPR as positioned to enter the clinic around the same time as Prime Medicine’s AATD program. However, while we believe that CRISPR’s approach and SYNTase technology are differentiated, we recognize the AATD development landscape is becoming increasingly crowded. Outside CTX460, we view CRISPR as having a catalyst-rich 12-month period ahead as Casgevy uptake continues and the company shares additional clinical data from its in vivo and ex vivo assets, including updated clinical data from CTX310 at AHA in November.
Needham
$81
Buy
23.25%
Upside
Reiterated
10/10/25
Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy RatingWe view the smaller size of the nucleic acid construct as an advantage leading potentially to higher editing efficiencies. Crispr intends to initiate clinical development mid-26' placing the company ~18 months behind Beam. Despite this advantage in timelines, demonstrating meaningfully higher serum AAT levels would support a competitive position. Disclaimers GIL BLUM, PH.D.
BMO Capital
$75
Buy
14.12%
Upside
Reiterated
09/23/25
J.P. Morgan
$70
Buy
6.51%
Upside
Initiated
09/18/25
Evercore ISI
$99
Buy
50.64%
Upside
Reiterated
08/25/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Chardan Capital
$82
Buy
24.77%
Upside
Reiterated
08/05/25
TD Cowen
$35→$40
Hold
-39.14%
Downside
Reiterated
08/05/25
Goldman Sachs
$48
Hold
-26.96%
Downside
Reiterated
08/05/25
Best Analysts Covering Crispr Therapeutics AG
1 Month
xxx
Success Rate
13/21 ratings generated profit
Average Return
+10.22%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +10.22% per trade.
3 Months
xxx
Success Rate
13/21 ratings generated profit
Average Return
+10.12%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +10.12% per trade.
1 Year
Success Rate
12/21 ratings generated profit
Average Return
+20.43%
reiterated a buy rating 3 months ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +20.43% per trade.
2 Years
xxx
Success Rate
12/19 ratings generated profit
Average Return
+4.49%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.16% of your transactions generating a profit, with an average return of +4.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CRSP Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
30
25
9
2
2
Buy
10
12
12
12
16
Hold
19
21
19
14
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
59
58
40
28
29
Each month's total comprises the sum of three months' worth of ratings.
CRSP Financial Forecast
CRSP Stock Forecast FAQ
What is CRSP’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is 71.50.
What is CRSP’s upside potential, based on the analysts’ average price target?
Crispr Therapeutics AG has 8.79% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CRSP a Buy, Sell or Hold?
Crispr Therapeutics AG has a consensus rating of Moderate Buy which is based on 11 buy ratings, 6 hold ratings and 0 sell ratings.
What is Crispr Therapeutics AG’s price target?
The average price target for Crispr Therapeutics AG is 71.50. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $99.00 ,the lowest forecast is $40.00. The average price target represents 8.79% Increase from the current price of $65.72.
The highest analyst price target is $99.00 ,the lowest forecast is $40.00. The average price target represents 8.79% Increase from the current price of $65.72.
What do analysts say about Crispr Therapeutics AG?
Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of CRSP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.